ProDERM Study: Successful Phase 3 Results in First and Only FDA-Approved IVIg Therapy for Dermatomyositis in Adults1-3

Octagam 10% is an immune globulin intravenous (human) liquid preparation indicated for the treatment of dermatomyositis (DM) in adults; Octagam 10% is also indicated for the treatment of chronic immune thrombocytopenic purpura (ITP) to rapidly raise platelet counts to control or prevent bleeding in adults.1

Why octagam 10%?

Ready to use, liquid preparation of highly purified human IVIg1

Data Driven Results

Significant and sustained improvement in Total Improvement Score (TIS) and disease severity demonstrated in a phase 3 trial1,2

Octagam boxes in a variety of sizes
Dosage and Administration

Review octagam 10% dosage and
administration in adult patients with DM

  1. Octagam 10% Full Prescribing Information. Paramus, NJ: Octapharma; rev March 2022.
  2. Octapharma. Data on file.
  3. Aggarwal R, et al. (ProDERM study). Submitted for publication. August 2021.